InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (10 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
10
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the complete record of transactions filed by Duncan Jason, Directeur Juridique. Officer active across 1 company, notably Albireo Pharma, INC.. Aggregated, 15 disclosures have been published. Breakdown: 0 buy · 10 sells. Total volume traded: €84k. Activity tracked since 24 June 2021. The latest transaction was disclosed on 19 January 2023 (Attribution). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Duncan Jason
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations15 total
3,296 sharesCommon StockSEC:0001209191-23-014741:0
55,000 shares0Common StockSEC:0001209191-23-005335:0
55,000 shares0Common StockSEC:0001209191-23-004950:0
228 shares@ US$43.802.0% of flowCommon StockSEC:0001209191-23-004451:0
938 shares@ US$43.90448.2% of flowCommon StockSEC:0001209191-23-004223:0
104 shares@ US$19.57640.4% of flowCommon StockSEC:0001209191-22-054490:0
96 shares@ US$19.53760.4% of flowCommon StockSEC:0001209191-22-054490:1
456 shares@ US$19.39631.9% of flowCommon StockSEC:0001209191-22-054490:2
106 shares@ US$24.67730.5% of flowCommon StockSEC:0001209191-22-043100:0
240 shares@ US$33.072.7% of flowCommon StockSEC:0001209191-22-025522:0
416 shares@ US$24.88223.4% of flowCommon StockSEC:0001209191-22-004809:0
10,800 shares0Common StockSEC:0001209191-22-004060:0
95 shares@ US$28.85080.9% of flowCommon StockSEC:0001209191-21-061556:0
90 shares@ US$34.131.0% of flowCommon StockSEC:0001209191-21-048160:0
9,137 shares@ US$24.0468.6% of flowCommon StockSEC:0001209191-21-043467:0
15 of 15 declarations
About Duncan Jason
Duncan Jason is Directeur Juridique and Chief Legal Officer and GC at Albireo Pharma, INC. He has 15 filings in total, and in the sampled recent filings covering the period from 2021-06-28 to 2023-03-02, the reported amounts are EUR 0 in purchases and EUR 84211 in sales, with cession as the dominant transaction nature.
